Touyun Biotech Group Limited issued a positive profit alert for the six months ended 30 June 2026, indicating that profit and total comprehensive income attributable to owners are expected to land between HK$180.00 million and HK$200.00 million. This compares with HK$16.00 million in the same period of 2025, implying year-on-year growth of approximately 1,025%–1,150%.

Management attributes the sharp increase primarily to a substantial fair value gain of about HK$340.00 million on financial assets at fair value through profit or loss, covering both listed and unlisted equity investments. In the prior-year interim period, the comparable gain was roughly HK$73.00 million.

The unaudited figures are based on preliminary management accounts and remain subject to audit committee review. Touyun Biotech plans to release its full interim results by the end of August 2026.

The board advises shareholders and potential investors to exercise caution when dealing in the company’s shares.